US · CERS
Cerus Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Concord, CA 94520
- Website
- cerus.com
Price · as of 2024-12-31
$2.72
Market cap 491.74M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.40 | +980.88% |
| Intrinsic Value(DCF) | $2.22 | -18.38% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $2.59 | $27.79 | $0.44 | $0.00 | $0.00 |
| 2011 | $3.73 | $29.38 | $0.38 | $0.00 | $0.00 |
| 2012 | $4.23 | $28.26 | $0.36 | $0.00 | $0.00 |
| 2013 | $6.11 | $24.18 | $0.50 | $0.00 | $0.00 |
| 2014 | $4.12 | $27.60 | $0.16 | $0.00 | $0.00 |
| 2015 | $5.65 | $26.50 | $0.41 | $0.00 | $0.00 |
| 2016 | $4.45 | $25.99 | $0.04 | $0.00 | $0.00 |
| 2017 | $4.87 | $27.32 | $0.00 | $0.00 | $0.00 |
| 2018 | $6.48 | $32.16 | $0.46 | $0.00 | $0.00 |
| 2019 | $5.49 | $26.42 | $0.05 | $0.00 | $0.00 |
| 2020 | $6.39 | $29.47 | $1.90 | $0.00 | $0.00 |
| 2021 | $5.22 | $31.07 | $44.03 | $0.00 | $0.00 |
| 2022 | $2.80 | $27.95 | $55.49 | $0.00 | $0.00 |
| 2023 | $2.26 | $25.36 | $11.89 | $0.00 | $0.00 |
| 2024 | $1.51 | $29.40 | $3.61 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cerus Corporation's (CERS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.40
- Current price
- $2.72
- AI upside
- +980.88%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.22
-18.38% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CERS | Cerus Corporation | $2.72 | 491.74M | +981% | -18% | — | — | -13.30 | 4.96 | 1.55 | -29.56 | — | 5.08 | 55.21% | -7.89% | -11.60% | -38.53% | -18.17% | -10.52% | 1.75 | -1.60 | 2.39 | 1.73 | -7.76 | -4762.00% | 1529.00% | -11784.00% | 3.06% | 0.18 | 10.88% | 0.00% | 0.00% | 2.34% | -20.83 | 34.77 | 1.64 | -5.07 |
| CVRX | CVRx, Inc. | $8.16 | 214.7M | +209% | -60% | — | — | -4.02 | 5.45 | 3.78 | -3.70 | — | 5.45 | 85.33% | -90.49% | -94.10% | -96.59% | -342.22% | -44.76% | 1.29 | -8.80 | 7.63 | 6.49 | 0.49 | -2302.00% | 1045.00% | 60.00% | -19.01% | -3.02 | -272.03% | 0.00% | 0.00% | 0.00% | -3.70 | -4.65 | 3.35 | -5.99 |
| MASS | 908 Devices Inc. | $6.90 | 249.73M | +193% | -84% | — | — | -1.30 | 0.82 | 1.58 | -0.71 | -1.49 | 1.36 | 50.18% | -128.65% | -121.09% | -51.56% | -197.59% | -39.84% | 0.06 | — | 4.10 | 3.27 | 0.85 | 8761.00% | 1872.00% | 1382.00% | -32.80% | -1.20 | -79.76% | 0.00% | 0.00% | 0.00% | -0.40 | -1.01 | 0.52 | -1.50 |
| NPCE | NeuroPace, Inc. | $14.58 | 485.63M | +102% | +40% | — | — | -11.80 | 39.98 | 4.01 | -20.57 | — | 39.98 | 73.94% | -27.12% | -33.97% | -189.35% | -78.53% | -26.83% | 9.15 | -2.46 | 5.37 | 4.33 | -3.61 | -2677.00% | 2214.00% | -815.00% | -5.70% | -1.18 | -66.15% | 0.00% | 0.00% | 0.00% | -15.73 | -18.68 | 4.27 | -4.71 |
| QTRX | Quanterix Corporation | $6.55 | 305.96M | +237% | -22% | -45% | — | -7.37 | 0.86 | 2.10 | -0.73 | -45.26 | 0.87 | 59.89% | -38.85% | -28.45% | -11.33% | -70.92% | -9.23% | 0.11 | — | 8.66 | 7.65 | 0.44 | 1628.00% | 1180.00% | 6982.00% | -13.57% | -0.84 | -51.94% | 0.00% | 0.00% | 0.00% | -0.61 | -0.83 | 0.24 | 1.46 |
| RXST | RxSight, Inc. | $7.48 | 307.55M | +291% | -36% | -74% | — | — | 1.14 | 2.33 | -2.43 | — | 1.14 | 76.60% | -35.84% | -28.96% | 0.00% | -83.88% | 0.00% | 0.04 | -1204.75 | 10.95 | 9.58 | 0.22 | 3380.00% | -389.00% | -1360.00% | -6.17% | -0.59 | -33.66% | 0.00% | — | 1.44% | -2.00 | -4.98 | 0.72 | 3.16 |
| SENS | Senseonics Holdings, Inc. | $8.27 | 337.9M | +200% | +728% | — | — | -5.18 | -24.61 | 18.13 | -5.73 | -38.01 | -23.91 | 2.37% | -333.05% | -349.84% | -817.17% | 267.39% | -65.88% | -3.69 | -8.87 | 2.35 | 2.13 | 0.20 | 1364.00% | 37.00% | -1107.00% | -15.39% | -1.56 | 224.02% | 0.00% | 0.00% | 0.00% | -5.26 | -6.28 | 17.53 | -12.73 |
| SGHT | Sight Sciences, Inc. | $5.16 | 272.82M | +483% | -76% | — | — | -2.30 | 1.35 | 1.48 | -0.83 | — | 1.35 | 85.50% | -63.27% | -64.49% | -49.59% | -403.80% | -33.29% | 0.46 | -10.84 | 9.04 | 8.48 | 1.74 | -965.00% | -147.00% | -5261.00% | -19.22% | -1.44 | -181.68% | 0.00% | 0.00% | 0.00% | -0.76 | -1.69 | 0.48 | -1.67 |
| SNWV | SANUWAVE Health, Inc. | $24.33 | 208.62M | +2,106% | +2,696% | — | — | -4.13 | -10.18 | 3.97 | -8.74 | — | -5.46 | 75.23% | 16.60% | -96.13% | 112.25% | -90.44% | -119.43% | -2.00 | 0.40 | 0.43 | 0.32 | -0.92 | -4233.00% | 5999.00% | -14330.00% | 1.52% | 0.06 | -32.81% | 0.00% | 0.00% | 10.35% | 26.71 | 73.63 | 4.43 | -9.15 |
| TBRG | TruBridge, Inc. | $19.29 | 289.52M | +494% | -41% | — | — | -19.81 | 2.40 | 1.18 | 16.24 | — | -3.32 | 50.81% | 1.94% | -5.97% | -11.59% | 1.86% | -4.95% | 1.04 | 0.41 | 1.70 | 1.34 | 4.65 | -5619.00% | 95.00% | -15833.00% | 3.22% | 0.61 | 3.65% | 0.00% | 0.00% | 9.23% | 85.50 | 43.52 | 1.66 | 2.06 |
| TKNO | Alpha Teknova, Inc. | $2.58 | 138.11M | +974% | -63% | — | — | -7.38 | 1.85 | 3.14 | -13.45 | — | 2.24 | 33.17% | -41.90% | -42.59% | -22.83% | -21.20% | -15.52% | 0.22 | -23.91 | 4.58 | 1.40 | -0.91 | -4386.00% | 735.00% | -3170.00% | -7.25% | -1.07 | -11.53% | 0.00% | 0.00% | 13.58% | -8.04 | -14.79 | 3.37 | 0.52 |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
- CEO
- William Greenman
- Employees
- 614
- Beta
- 1.53
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.22 ÷ $2.72) − 1 = -18.38% (DCF, example).